Ariflo SmithKline beecham pic

IDrugs

Volumn 2, Issue 9, 1999, Pages 915-924

  Brown, William ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 BIS(HYDROXYMETHYL)NAPHTHALENE LIGNAN; CILOMILAST; DENBUFYLLINE; INDAZOLE DERIVATIVE; NITRAQUAZONE; OVALBUMIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PRANLUKAST; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; XANTHINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MYCOSIS; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VOMITING;

EID: 0032856957     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (137)

1. 2399 Phosphodiesterase inhibitors: New opportunities for the treatment of asthma. Torphy TJ, Undem BJ THORAX 1991 46 512-523
2. 3146 Investigation into the role of phosphodiesterase 4 in bronchorelaxation,''including studies with human bronchus. Cortijo J, Bou J, Beleta J, Cardelus I, Uenas J, Morcillo E, Gristwood RW BRJ PHARMACOL 1993 108 562-568
3. 13324 Differential pharmacologie sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Silver PJ, Hamel LT, Perrone MH, Bentiey RG, Bushover CR, Evans DB EUR J PHARMACOL 1988 150 1-2 85-94
4. 32643 Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Nicholson CD, Challiss RAJ, Shahid M TRENDS PHARMACOL SC11991 12 19-27
5. 66809 Results of a phase II study of the antidepressant effect of rolipram. Zeller E; Stief HJ, Pflug B, Sastre-y-Hemandez M PHARMACOPSYCHIATRY1984 17 188-190
6. 159713 Selective type 4 phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogs. Ashton MJ, Cook DC, Fenton G, Karisson JA, Palfreyman MN, Raebum D, Ratcliffe AJ, Souness JE, Thurairatham S, Vicker N J MED CHEM 19943711 1696-1703 • SAR study describing the synthesis of RP-73401
7. 170042 SB to file seven NDAs, launch Havrix hepatitis A vaccine in 1995; no major drugs come off patent through 2000; genomics work has synergy with diagnostics. FDC REPORTS PINK SHEET 1994 56 51 17
8. 171208 SB claims top R&D performance. SCRIP 1995 1992 1213
9. 188287 SB-207499. Bamette M WORLD CONGRINFLAMM1995 2 Symposium 14 Talk 478
10. 188433 Research and Development Review - SB Pharmaceuticals mid-stage development portfolio: products in phase II clinical trials. SmithKline Beschäm COMPANY BROCHURE 1995 October 2
11. 188478 Research and Development Review - SB Pharmaceuticals: development portfolio by therapeutic area. SmithKiine Beecham COMPANY BROCHURE 1995 October 2
12. 189121 The ability of phosphodiesterase 4 inhibitors to suppress Superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase 4 catalytic activity. Bamette MS, Manning CD, Cieslinski LB, Burman M, Christensen SB, Torphy TJ J PHARMACOL EXP THER 1995 273 2 674-679 • Study that correlates the ability of PDE4 inhibitors to suppress Superoxide production in eosinophils with the inhibition of PDE 4 catalytic activity.
13. 190832 Phosphodiesterase type IV inhibitors as antiinflammatory agents. Palfreyman MN DRUGS FUTURE 1995 20 8 793-804 • Review of phosphodiesterase type 4 inhibitors as antiinflammatory agents describes the synthesis of SB-207499, among others.
14. 191084 Characterization of Org-20241, a combined phosphodiesterase IV/lll cyclic nucleotide phosphodiesterase inhibitor for asthma. Nicholson CD, Shahid M, Bruin J, Barren E, Spiers I, Boer J De, Van Amsterdam RGM, Zaagsma J, Kelly JJ, pent G, Giembycz MA, Bames PJ J PHARMACOL EXP THER1995 274 2 678-687
15. 197831 Inflammation '95. Pamham MJ DRUG NEWS PERSPECT 199588514-520
16. 203772 Striving to make peoples lives better. SmithKline Beecham pic ANNUAL REPORT 1995 March
17. 204952 Novel phosphodiesterase inhibitors. EXP OPIN THER R4T199664411-414
18. 207557 New drugs in the R&D pipline. PHARMA JPN 1996 1498 14-15 • Phase I trials in Japan.
19. 211033 Cyclic nucleotides and phosphodiesterases and airway function. Bames PJ EUR RESPIR J1995 8 3 457-462
20. 215751 Third International Conference on Cyclic Nucleotide Phosphodiesterases: From Genes to Therapies. IDDB MEETING REPORT 1996 July 18-21
21. 216622 Selective phosphodiesterase inhibitors in the therapy of asthma. Dent G, Giembycz MA CLIN IMMUNOTHER1995 3 6 423437
22. 217903 Molecular approaches toward improving the therapeutic index of PDE4 inhibitors. Torphy TJ, Bamatte MS, Christensen SB ACS 1996 212th Ortando MED1116
23. 224628 Therapeutic approaches to allergic and inflammatory diseases: Fourth Annual Midwest Meeting of the Inflammation Research Association. Glaser KB, Hulkower Kl, Carison RP 1NFLAMM RES 1996 45 9 438-441
24. 224629 Subtypes of the type 4 cAMP phosphodiesterases: Structure, regulation and selective inhibition. Muller T, Engels P, Fozard JR TRENDS PHARMACOL SC11996 178 294-298 • Review describing the subtypes of PDE4.
25. 228805 IBC Conference: Asthma and Allergy: Advances in Understanding and Novel Therapeutic Approaches. IDDB MEETING REPORT 1996 December 9-10 • Conference report on novel approaches to the therapy of asthma and allergy.
26. 243338 SmithKline Beecham pic ANNUAL REPORT 1996 April 22
27. 248285 New drugs in the R&D pipeline: SmithKline Beecham Seiyaku. PHARMA JPN 1997 1550 17 • Positive phase II results reported.
28. 253116 Anti-inflammatory drugs and Alzheimer's disease. Brown F, James S, Roberts GW ALZHEIMER'S DISEASE ID RESEARCH ALERT 1997 2 4 195-206
29. 254489 Phosphodiesterase (PDE)4 inhibitors: Antiinflammatory drugs of the future? Teixeira MM, Gristwood RW, Cooper N, Hellewell PG TRENDS PHARMACOL SCI 1997 18 5 164-170 • Review of PDE4 inhibitors.
30. 254490 In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. Cohan VL, Showell HJ, Fisher DA, Pazoles CJ, Watson JW, Turner CR, Cheng JB J PHARMACOL EXP THER 1996 278 3 1356-1361 • Comparative study of in vitro pharmacology of different PDE IV inhibitors.
31. 254503 Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ MOL PHARMACOL 1996 50 4 891-899
32. 256850 SB-207499, a potent and selective phosphodiesterase (PDE) 4 inhibitor, suppresses activities of several Immune and inflammatory cells. Bamette MS AM J RESPIR CRIT CARE MED 1994149 A209 • Abstract on in vitro pharmacology of SB-207499.
33. 256851 Biarylcarboxamide inhibitors of phosphodiesterase 4 and tumor necrosis factor-α. Chambers RJ, Marfat A, Cheng JB, Cohan VL, Damon DB, Duplantier AJ, Hibbs TA, Jenkinson TH, Johnson KL, Kraus KG, Pettipher ER BIOORGANIC MED CHEM LETT 1997 7 7 739-744 • Short study of inhibitors of PDE IV and TNFa.
34. 256852 Profile of SB-207499, a selective inhibitor of phosphodiesterase (PDE) 4, in antigen-induced bronchoconstriction and eosinophil Influx in the guinea pig. Underwood DC et al AM J RESPIR CRIT CARE MED 1994 149 A762 • Abstract on in vivo pharmacology of SB-207499.
35. 256854 SB development portfolio. COMPANY BROCHURE 1997 June
36. 256932 Molecular aspects of inhibitor interaction with PDE4. Christensen SB et al PHOSPHODIESTERASE INHIBITORS 1996 • Comparative study on molecular aspects of inhibitor interaction with PDE4.
37. 263419 T-440. Graul A, Leeson P, Castaner J DRUGS FUTURE 1997227729-732
38. 264381 Conquering airway inflammation in the 21st century, National Heart and Lung Institute, London, UK. IDDB MEETING REPORT1997 September 15-17
39. 265704 European Respiratory Society Annual Congress, Berlin, Germany. IDDB MEETING REPORT 1997 September 20-24
40. 266552 Phosphodiesterase 4 inhibitors for the treatment of asthma. Karisson JA, Aldous D EXP OPIN THER PAT 1997 7 9 989-1003 • Comprehensive review of the PDE4 area.
41. 277116 Arch rivals give good product pipeline mix. SCRIP 1998 23068
42. 284430 New therapeutic approaches for allergic diseases of the respiratory tract - Institut Pasteur EuroConferences, Paris, France. IDDB MEETING REPORT 1998 April 1-4
43. 284490 SmithKline Beecham R&D review meeting. IDDB MEETING REPORT 1998 April 16
44. 284704 Anti-metastatic activity of BAY-12-9566 in a human colon carcinoma HCT116 orthotopic model. Rynn C, Bull C, Eberwein D, Matheme C, Hibner B PRESS RELEASE 1998 April 21
45. 285142 1,4-cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. Christensen SB, Guider A, Forster CJ, Gleason JG, Bender PE, Karpinski JM, DeWolf Jr WE, Bamette MS, Underwood DC, Griswold DE, Cieslinski LB et al J MED CHEM 1998 41 6 821 -835
46. 285376 Avandia anti-diabetic NDA filing planned by early 1999, SB says. FDC REPORTS PINK SHEET 1998 60 16 9
47. 285766 SB unveils new compounds in pharma R&D portfolio. SCRIP 1998 2329 19 286965 American Thoracic Society 1998 International Conference, Chicago, IL, USA. IDDB MEETING REPORT 1998 April 24-29
48. 287219 New indazole derivatives as phosphodiesterase type 4 inhibitors. EXP OPIN THER PAT 1998 8 5 605-608
49. 288981 Effect of PDE4 inhibitors on zymosan-Induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Au B T,. Teixeira MM. Collins PD, Williams TJ BR J PHARMACOL 1998 123 6 1260-1266
50. 290389 New therapies for chronic obstructive pulmonary disease. Barnes PJ THORAX 1998 53 2 137-147
51. 290973 7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase. Duplanlier A, Andresen C, Cheng J, Cohan VL, Decker C, DiCapua FM, Kraus KG, Johnson KL, Turner CR, UmLand JP, Watson JW et a/J/W£DCH£M199841 31 2268-2277
52. 291288 PDE4 inhibitors 1998. Norman P EXP OPIN THER PAT 199887771-784
53. 291342 Recent advances in preclinical drug development in multiple sclerosis. Hoban CJ EXP OPIN THER PAT 1998 8 7 831-854
54. 291853 COPD: new developments and therapeutic opportunities, National Heart and Lung Institute, London, UK. IDDB MEETING REPORT 1998 July 7-8
55. 293502 Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Pauwels RA, Yemault JC, Demedts MG, Geusens P AM J RESPIR CRIT CARE MED 1998 1573827-832
56. 296323 Potential of phosphodiesterase type 4 inhibitors in the treatment of rheumatoid arthritis. Souness JE, Foster M CURR RES RHEUMATOID ARTHRITIS 1998 2 6 255-268
57. 299419 Conquering Airway Inflammation in the 21st Century (Part I), National Heart & Lung Institute, London, UK. IDDB MEETING REPORT 1998 September 14-16
58. 300145 New Drugs in the R&D pipeline - SB Seiyaku. PHARMA JPN1998161617:17
59. 300257 Global pharmaceuticals. The haves and have nots. Merrill Lynch ANALYST REPORT1998 Septembers
60. 301142 Conquering airway inflammation in the 21st century (Part II), National Heart and Lung Institute, London, UK. IDDB MEETING REPORT-\99B September 14-16
61. 301202 Clinical aspects and modern management of asthma IBC Conference, National Heart & Lung Institute, London, UK. IDDB MEETING REPORT 1998 October 6-7
62. 302048 Pharmaceuticals. Safe haven = further outperformance. Merrill Lynch ANALYST REPORT 1998 July 3
63. 302158 SmithKline Beecham reports third quarter 1998 reults; performance driven by increased volume and continued new product momentum. SmithKline Beecham pic PRESS RELEASE 1998 October 20
64. 303058 Potential of phosphodiesterase type 4 inhibitors in the treatment of rheumatoid arthritis. Souness JE, Foster M IDRUGS 199815541-553
65. 304536 SB-207499. Anti-asthmatic/antl-inflammatory phosphodiesterase 4 inhibitor. Silvestre J, Graul A, Castaner J DRUGS FUTURE 1998 23 6 607-615
66. 304537 SB-207499 (Ariflo), a potent and selective secondgeneration phosphodiestcrase 4 inhibitor: in vitro antiinflammatory actions. Bamette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey Sobotka A, Torphy TJ J PHARMACOL EXP THER1998 284 1 420-426
67. 304539 Phosphodiesterase isozymes molecular targets for novel antiasthma agents. Torphy TJ AM J RESPIR CRIT CARE MED 1998 157 2 351-370 • Extensive, up-to-date review of PDEs and PDE inhibitors, highlighting PDE4 and its inhibitors, and including a well-balanced view of the clinical prospects for PDE4 inhibitors in asthma.
68. 304543 Phosphodiesterase inhibition improves agonistinduced relaxation of hypertensive pulmonary arteries. Wagner RS, Smith CJ, Taylor AM, Rhoades RA J PHARMACOL EXP THER 199728231650-1657
69. 304546 Molecular basis for an improved therapeutic index of SB 207499, a second generation Phosphodiesterase 4 inhibitor. Torphy TJ, Christensen SB, Bamette MS, Burman M, Cieslinski LB, Dewolf Jr WE EUR RESPIR J SUPPL 1997 10 25 313S
70. 304548 SB-207499, a second-generation phosphodiesterase 4 inhibitor, reduces TNFcc and IL-4 production in vivo. Griswold DE, Tzimas MN, Badger AM, Gorycki PD, Levandoski PA, Torphy TJ EUR RESPIR J SUPPL 1997 10 25 313S
71. 304550 Anti-asthmatic potential of the second-generation phosphodiesterase 4 inhibitor, SB-207499. Underwood DC, Bochnowicz S, Osbom R, Hay D, Gorycki PD, Christensen SB, Torphy TJ EUR RESPIR J SUPPL 199710 25 313S
72. 304551 Anti-inflammatory actions of SB-207499, a novel secondgeneration phosphodiesterase 4 inhibitor. Bamette MS, Christensen SB, Grous M, Prabhakar U, Rush JA, Essayan DM, Kagey Sobotka A, Torphy TJ EUR RESPIR J SUPPL 199710 25 313S
73. 304552 Type 4 phosphodiesterase inhibitors and their potential in the treatment of inflammatory disease. De Britof B, Souness JE, Warne PJ EMERGING DRUGS'19972 249-268
74. 311130 Pharmaceutical & Biotechnology Bulletin. Merrill Lynch ANAL YST REPORT 1998 November 2
75. 311957 p-Adrenoceptors, cAMP and airway smooth muscle: challenges to the dogma. Torphy TJ TRENDS PHARMACOL SCI 19941510370-374 • Concise review of the different mechanisms by which β1adrenoceptors relax airway smooth muscle.
76. 311958 Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma? Dent G, Giembycz MA THORAX 1996 51 6 647-649
77. 314138 Differential ability of PDE4 inhibitors in preventing antigen-induced bronchospasm In guinea-pigs. J ALLERGY CLIN IMMUNOL 1999 103 1 Abs 485
78. 314372 Pharmaceutical device & biotechnology bulletin. Merrill Lynch ANALYST REPORT1999 Februarys
79. 314953 SB-207499 (Ariflo), a second-generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma. Nieman RB, Fisher BD, Amit O, Dockhom RJ AM J RESPIR CRIT CARE MED 1998 157 413
80. 315260 Substituted furans as inhibitors of the PDE4 enzyme. Perrier H, Bayly C, Laliberte F, Huang Z, Rasori R, Robichaud A, Girard Y, Macdonald D B1OORGANIC MED CHEM LETT 1999 9 3 323-326
81. 316213 Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Manganiello VC, Murara T, Taira M, Beifrage P, Degerman E ARCH BIOCHEM BIOPHYS1995 322 1 1 -13
82. 316222 Molecular cloning of a novel splice variant of human type 4A (PDE4A) cyclic AMP phosphodiesterase and localization of the gene to the p13.1-q12 region of human chromosome 19. Horton YM, Sullivan M, Houslay MD BIOCHEM J 1995308 683-691
83. 316232 Novel selective PDE4 inhibitors as anti-asthmatic agents. Synthesis and biological activities of a series of 1-aryl2,3-bis(hydroxymethyl)napthalene lignans. Iwasaki T, Kondo K, Kuroda T, Moritani Y, Yamagata S, Sugiura M, Kikkawa H, Kaminuma O, Ikezawa K J MED CHEM1996 39 2696-2704
84. 316238 Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. Turner CR, Andresen CJ, Smith WB, Watson JWAMJ RESPIR CR1T CARE MED 1994149 1153-1159
85. 316269 Modulation of relaxant responses evoked by a nitric oxide donor and by nonadrenergic, noncholinergic stimulation by isozyme-selective phosphodiesterase inhibitors in guinea pig trachea. Ellis JL, Conanan ND J PHARMACOL EXP THER 19951995272997-1004
86. 316276 Molecular mechanisms of -adrenergic relaxation of airway smooth muscle. Kotlikoff Ml, Kamm KE ANNU REV PHVS/OJ.199658115-141
87. 316277 Assessment of signal transduction mechanisms regulating airway smooth muscle contractility. Schramm CM, Grunstein MM AM J PHYS LUNG CELL MOL PHYSIOL 1992 262 116-139
88. 316279 Role of multiple cAMP-specific phosphodiesterase variants. Bushnik T, Conti M BIOCHEM SOC TRANS 1996 24 1014-1019
89. 316281 Comparison of phosphodiesterase 3, 4, and dual 3/4 inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. Underwood DC, Kotzer CJ, Bochnowicz S, Osbom RR, Luttmann MA, Hay DWP, Torphy TJ J PHARMACOL EXP THER 1994 270 250-259
90. 316284 Differential,regulation of human antigen-specific TH 1 and TH 2 lymphocyte responses by Isozyme selective cylic nucletide phosphodiesterase inhibitors. Essayan DM, KageySobotka A, Lichtenstein LM, Huang S-K J PHARMACOL EXP THER 1997282505-512
91. 316287 Characterization of the memory gene Dunce of Drosophila melanogaster. Qiu Y, Cher, C-N, Malone T, Richter L, Beckendorf SK, Davis RL J MOL B1OL 1991 222 553-565
92. 316289 Inflammatory mediators and asthma. Bames CJ, Chung KF, Page CP PHARMACOL REV 1988 40 49-78
93. 316292 A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets of antidepressant drugs. Böiger G, Michaeli T, Martins T, St John T, Steiner B, Rodgers L, Riggs M, Wigler M, Ferguson K MOL CELL BIOL 1993 13 65586571
94. 316293 Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [H]R-(-)-rolipram binding by selective inhibitors. Kelly JK, Bames PJ, Giembycz MA BIOCHEM J 1996 318 425-436
95. 316318 Theophylline and selectivity PDE inhibitors as bronchodilators and smooth muscle relaxants. Rabe KF, Magnussen H, Dent G EUR RESPIR J1995 8 637-642
96. 316522 Genetic dissection of the learning/memory gene dunce of Drosphila melanogaster. Qui Y, Davis RL GENES DEV1993 7 1447-1458
97. 316523 Anti-Inflammatory effects of low dose oral theophylline In atopic asthma. Sullivan P, Bekir S, Jaffar Z, Page CP, Jeffery P, Costello J LANCET 1994 343 1006-1008
98. 316524 Treatment of chronic asthma with theophylline. Weinberger M IS) ATLAS SCI: PHARMACOL 1988 2 53-61
99. 316578 SB-207499 (Ariflo), a second-generation phosphodiesterase 4 inhibitor, reduced tumor necrosis factor a and interlukin-4 production in vivo. Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Bamette MA, Graus M, Christensen S, Torphy TJ J PHARMACOL EXP THER 1998 287 705-711
100. 316589 Anti-asthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB-207499 (Ariflo) in the guinea pig. Underwood DC, Bochnowiz S, Osbom RR, Kotzer CJ, Luttman MA, Hay DWP, Gorycki PD, Christensen SB, Torphy TJ J PHARMACOL EXP THER 1998 287 988-995
101. 316599 Subcellular localization of rolipram-sensitive, cAMPspecific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene. Jin S-LC, BushnikT, Lan L, Conti M J BIOL CHEM1998 273 19672-19678
102. 316601 SB-207499 (Ariflo), a second-generation phosphodiesterase 4 inhibitor, suppresses the production of pro-inflammatory cytokines. Bamette MS, Griswold DE, Essayan DM, Christensen SB, Torphy TJ AM J RESP1R CRIT CARE MED 1998157828
103. 316602 The safety and tolerability of Ariflo (SB-207499), a novel and selective phosphodiesterase 4 inhibitor, in healthy male volunteers. Murdoch RD, Cowley H, Upward J, Webber D, Wyld P AM J RESPIR CRIT CARE MED 1998 157 409
104. 317058 Preview of the American Chemical Society - 217th National Meeting Anaheim, CA, USA. Kubinyi H, McCall J, Witczak Z, Agathangelou P IDDB MEETING REPORT 1999 March 21-25
105. 317192 SB savings from streamlining will approximate 1998 Kytril sales. FDC REPORTS PINK SHEET 1999 61 7 17-18
106. 317239 Overview of effects of theophylline. Persson CGA J ALLERGY CLIN IMMUNOL 1986 78 780-787
107. 317250 Rolipram in major depression: results of a double-blind comparative study with amitriptyline. Eckmann F, Fichte K, Meya U, Sastre-y-Hemandez M CURR THER RESEARCH 1988 43 291295
108. 317564 American Academy of Asthma, Allergy and Immunology - 55th Annual Meeting, Orlando, FL, USA. LJeberman P IDDB MEETING REPORT 1999 February 26-March 3
109. 317577 ABN Amro Pharmaceutical Sector Research SmithKline Beecham. ANALYST REPORT 1999 Februarys
110. 318120 American Academy of Asthma Allergy and Immunology
111. - 55th Annual Meeting (Part II), Orlando, FL, USA. Gibson PG IDDB MEETING REPORT 1999 February 26-March 3
112. 318284 Comparison of the PDE4 activities of Ariflo (SB-207488) with those of 1,3-substituted cyclohexane carboxylate analogs.
113. Christensen SB, Forster CJ, Bender PE, Guider A, Karpinski JM, Bamette MS, Bochnowicz S, Burman M, Cieslinski LB, Underwood DC, Torphy TJ ACS 1999 217 Anaheim MEDI 201
114. 318684 Evolution of Ariflo (SB-207499), a second-generation PDE4 inhibitor for the treatment of asthma and COPD. Christensen SB, Bamette MS, Underwood DC, Murdoch RD, Nieman RB, Compton CJ, Torphy TJ ACS 1999 217 Ananeim MEDI 269
115. 319722 American Chemical Society 217th National Meeting (Part VIII): Viral Proteases and Phosphorodiesterase Inhibitors, Anaheim, CA, USA. Agathangelou P IDDB MEETING REPORT 1999 March 25
116. 321694 Novel, potent, and selective phosphodiesterase-4 inhibitors as anti-asthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives. Ukita T, Sugahara M, Terakawa Y, Kuroda T, Wada K, Nakata A, Ohmachi Y, Kikkawa H, Ikezawa K, Nailo K J MED CHEM1999 42 6 1088-1099
117. 322061 SmithKline Beecham reports earnings per share increase of 15% for first quarter 1999,13% excluding currency. SmithKline Beecham pic PRESS RELEASE 1999 April 20
118. 322439 Current Drugs summary of the American Chemical Society 217th National Meeting, Anaheim, CA, USA. Garratt J, Agathangelou P IDDB MEETING REPORT 1999 March 21-25
119. 322822 SmithKline Beecham - first quarter meets best expectations. Merrill Lynch ANALYST REPORT 1999 April
120. 323259 Annual Report 1998. SmithKline Beecham pic ANNUAL REPORT 1999 April 30
121. 323686 SmithKline Beecham - all and more. Merrill Lynch ANAL YST REPORT 1999 April 23
122. 324320 American Thoracic Society/American Lung Association 1999 International Conference: new drugs for airway inflammatory disease, San Diego, USA. O'Donnell S IDDB MEETING REPORT 1999 April 23-28
123. 327601 International Union Against Tuberculosis and Lung Disease (IUATLD) - 20th Eastern Region Conference, Hong Kong. Seale P IDDB MEETING REPORT 1999 June 4-7
124. 328072 Annual Report and Accounts 1998 - SmithKline Beecham. SmithKline Beecham pic ANNUAL REPORT 1998 December 31 j.
125. 328112 SmithKIine Beecham - Web Page. SmithKline Beecham pic COMPANY WORLD WIDE WEB SITE 1999 June 16
126. 328675 COPD: New Developments & Therapeutic Opportunities, National Heart & Lung Institute, London, UK
127. Norman P IDDB MEETING REPORT 1999 June 14-16
128. 328676 Pan-European pharmaceutical review AB N AMRO ANALYST REPORT 1999 April
129. 328689 ABN Amro: pharmaceutical sector research: irritable bowel syndrome review. ABN Amro ANALYST REPORT 1999 May 26
130. 329981 Phosphodiesterase 4 inhibitors for the treatment of pulmonary diseases: from research to clinic. Torphy TJ MEDIATORS 1NFLAMM1999 8 Supp! 1 S-04-01
131. 329993 Ariflo (SB-207499) inhibits neutrophil-mediated pulmonary inflammation in the guinea pig. Underwood DC, Osbom RR, Rieman DJ, Thomas HC, Hay DWP, Torphy TJ MEDIATORS /AFMMM1999 8 Suppl 1 S-04-07
132. 331824 Inflammation - Fourth World Congress (Part I), Paris, France. Kelly D IDDB MEETING REPORT 1999 June 27-30
133. 332607 EPHAR '99 - Second European Congress of Pharmacology (Part II), Budapest, Hungary. Worker C IDDB MEETING REPORT 1999 July 3-7
134. 333306 SmithKIine Beecham - SG Warbury. SG Warbury ANALYST REPORT 1999 April 1
135. 333842 Merril Lynch: SmithKIine Beecham: second quarter earnings release. Merril Lynch ANALYST REPORT1999 July 21
136. 334810 Therapeutic potential and strategies for inhibiting tumor necrosis factor a. Newton RC, Decicco CP J MED CHEM1999 42 132295-2317
137. 335293 PDE4 inhibitors 1999. Norman P EXP OPIN THER PAT 1999981101 -1118